Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Antiplatelets In The Wilderness After Mixed Results From DAPT Study

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA seems more concerned about mortality than most academics following trial of dual antiplatelet therapy after stenting; AstraZeneca sees potential opening for Brilinta.

You may also be interested in...

Longer Anti-Platelet Therapy Reduces Thrombosis Risks With Drug-Eluting Stents

In patients implanted with drug-eluting stents, dual antiplatelet drug therapy beyond one year significantly reduces the risks of stent thrombosis and major adverse cardiovascular and cerebrovascular events compared to aspirin alone, but also increase the risk of bleeding, the Dual Antiplatelet Therapy Trial show.

Industry Post-Stenting Antiplatelet Trial Gains $1.5 Million Boost From FDA

Study aims to identify optimum duration of anti-clotting drugs for stent patients; enrollment targeted at 20,000 patients.

CHARISMA Suggests Benefit Of Combo Antiplatelet Therapy In Patients With Established CV Disease

Overall study group, however, did not show reduction in risk in combined rate of death, heart attack or stroke from combination therapy of Plavix and low-dose aspirin.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts